Voyager Therapeutics, Inc. (VYGR) Insider Bernard Ravina Sells 10,980 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Bernard Ravina sold 10,980 shares of the company’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total value of $223,223.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Bernard Ravina also recently made the following trade(s):

  • On Thursday, July 20th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $54,900.00.
  • On Monday, September 11th, Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock. The stock was sold at an average price of $12.87, for a total value of $211,968.90.
  • On Tuesday, September 5th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $54,900.00.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/10/13/voyager-therapeutics-inc-vygr-insider-bernard-ravina-sells-10980-shares.html.

Several brokerages have commented on VYGR. Raymond James Financial, Inc. began coverage on Voyager Therapeutics in a research note on Thursday. They set an “outperform” rating and a $35.00 price target for the company. Evercore ISI began coverage on Voyager Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $12.00 price target for the company. BidaskClub upgraded Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. ValuEngine lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Finally, Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $26.29.

Institutional investors have recently bought and sold shares of the company. Hershey Trust Co. increased its stake in shares of Voyager Therapeutics by 163.0% in the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after purchasing an additional 8,921 shares during the period. Fiduciary Trust Co. increased its stake in shares of Voyager Therapeutics by 19.1% in the first quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock worth $1,437,000 after purchasing an additional 17,386 shares during the period. Wellington Management Group LLP increased its stake in shares of Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after purchasing an additional 19,450 shares during the period. Teachers Advisors LLC increased its stake in shares of Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after purchasing an additional 1,847 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Voyager Therapeutics by 114.4% in the first quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock worth $1,107,000 after purchasing an additional 44,599 shares during the period. Institutional investors and hedge funds own 40.70% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

What are top analysts saying about Voyager Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Voyager Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit